EQL PHARMA AB Cash Flow Reinvestment Rate
EQL PHARMA AB cash flow reinvestment rate. EQL PHARMA AB (7JK) has a Cash Flow Reinvestment Rate of 1.03x as of March 2026, reinvesting €17.22 Million (capex €17.22 Million ) from operating cash flow of €16.79 Million. See EQL PHARMA AB (7JK) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of EQL PHARMA AB (2022–2026)
Cash flow reinvestment rate of EQL PHARMA AB from 2022 to 2026. Historical reinvestment intensity for EQL PHARMA AB across 3 annual periods. Explore 7JK operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
EQL PHARMA AB Cash Flow Reinvestment Rate by Year (2022–2026)
EQL PHARMA AB cash flow reinvestment rate by year from 2022 to 2026. Year-by-year capital reinvestment analysis for EQL PHARMA AB. For the full cash flow conversion analysis, see how efficiently does EQL PHARMA AB generate cash.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2026 | 2.37x | €67.24 Million | €28.36 Million | €67.24 Million | ▲ +219.2% |
| 2023 | 0.74x | €20.51 Million | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €22.09 Million | €41.83 Million | €22.09 Million | — |